Replies to post #3160 on InMed Pharmaceuticals Inc (INM)

[lesgetrich]

GW Pharmaceuticals still hasn't gotten FDA approval and they lose money each quarter yet they're trading at $110/share. I'm beginning to think InMed might beat them to market LOL

In any event, it shows that they don't have to be generating drug revenues, particularly if they can commercialize their biosynthesis or bioinformatics processes. As they complete each step (e.g. each clinical trial) and show progress toward revenues and profitability, the pps will head up to a higher level.